Ondine Biomedical, Inc. (GB:OBI)
LSE:OBI
Top Page
Ondine Biomedical, Inc.
(LSE:OBI)
Select Model
Select Model
Rating:37Underperform
Price Target:
8.00 p
▼(-8.57% Downside)
Action:DowngradedDate:12/11/25
Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company's strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.
Positive Factors
Revenue Growth
A 70.94% year-over-year revenue increase signals durable top-line momentum and expanding customer adoption. Sustained revenue growth provides more runway to invest in commercialization and R&D, supports operating leverage over time and enables scale to absorb fixed costs.
Negative Factors
Negative Operating Cash Flow
Negative operating cash flow is a durable red flag: the business is not generating cash from core operations, forcing reliance on external financing or equity issuance. This constrains investment, risks dilution, and limits ability to scale or weather downturns without capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 70.94% year-over-year revenue increase signals durable top-line momentum and expanding customer adoption. Sustained revenue growth provides more runway to invest in commercialization and R&D, supports operating leverage over time and enables scale to absorb fixed costs.
Read all positive factors
Ondine Biomedical, Inc. (OBI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£57.02M
Dividend YieldN/A
Average Volume (3M)160.07K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth63.25%
EPS Growth8.94%
CountryUK
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding518,366,940
10 Day Avg. Volume119,918
30 Day Avg. Volume160,072
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)6.29
Price to Sales (P/S)21.10
P/FCF Ratio-2.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£12.20M
Ondine Biomedical, Inc. Business Overview & Revenue Model
Company Description
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-bas...
How the Company Makes Money
Ondine Biomedical generates revenue through the sale of its medical devices and systems, particularly the Steriwave system, to hospitals, clinics, and healthcare providers. The company may also engage in partnerships with healthcare organizations ...
Ondine Biomedical, Inc. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.71M | 2.05M | 1.20M | 638.00K | 2.57M | 1.79M |
| Gross Profit | 681.92K | 1.32M | 703.00K | 287.00K | 1.25M | 649.00K |
| EBITDA | -18.73M | -18.49M | -13.79M | -18.85M | -48.36M | -14.56M |
| Net Income | -19.26M | -19.10M | -14.41M | -19.37M | -50.09M | -16.27M |
Balance Sheet | ||||||
| Total Assets | 8.79M | 12.82M | 5.73M | 16.57M | 34.14M | 2.63M |
| Cash, Cash Equivalents and Short-Term Investments | 5.59M | 9.77M | 2.98M | 13.13M | 30.36M | 626.00K |
| Total Debt | 557.09K | 168.00K | 541.00K | 896.00K | 739.00K | 31.46M |
| Total Liabilities | 8.06M | 5.95M | 3.65M | 4.92M | 4.48M | 36.46M |
| Stockholders Equity | 728.73K | 6.88M | 2.08M | 11.64M | 29.66M | -33.81M |
Cash Flow | ||||||
| Free Cash Flow | -15.05M | -15.50M | -13.83M | -16.66M | -12.62M | -6.43M |
| Operating Cash Flow | -15.02M | -15.49M | -13.65M | -16.34M | -12.54M | -6.33M |
| Investing Cash Flow | -24.44K | -10.00K | -177.00K | -311.00K | -77.00K | 2.90M |
| Financing Cash Flow | 14.81M | 21.74M | 3.79M | -275.00K | 41.90M | 3.83M |
Ondine Biomedical, Inc. Technical Analysis
Negative
8.75
Price Trends
9.93
Positive
9.88
Positive
11.98
Negative
Market Momentum
0.16
Positive
50.13
Neutral
48.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBI, the sentiment is Negative. The current price of 8.75 is below the 20-day moving average (MA) of 10.79, below the 50-day MA of 9.93, and below the 200-day MA of 11.98, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 50.13 is Neutral, neither overbought nor oversold. The STOCH value of 48.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBI.
Ondine Biomedical, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £29.61M | -1.92 | -53.86% | ― | ― | ― | |
49 Neutral | £1.11B | -8.50 | -29.43% | ― | 22.03% | 20.01% | |
44 Neutral | £25.27M | -54.98 | -10.01% | ― | 283.74% | 78.57% | |
42 Neutral | £298.31M | -1.74 | -361.23% | ― | ― | ― | |
41 Neutral | £77.27M | -4.89 | -63.53% | ― | 198.49% | -26.66% | |
37 Underperform | £57.02M | -2.25 | -506.43% | ― | 63.25% | 8.94% |
* Healthcare Sector Average
GB:OBI
Ondine Biomedical, Inc.
11.00
2.00
22.22%
GB:AVCT
Avacta Group plc
68.20
32.20
89.44%
GB:SBTX
SkinBioTherapeutics
9.75
-8.95
-47.86%
GB:4BB
4basebio UK Societas
499.00
-651.00
-56.61%
GB:POLB
Poolbeg Pharma Ltd.
4.20
1.50
55.56%
GB:ONT
Oxford Nanopore Technologies PLC
114.50
9.50
9.05%
Ondine Biomedical, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Ondine’s Steriwave Shortlisted for 2025 Bionow Product of the Year
Positive
Feb 2, 2026
Ondine Biomedical’s flagship nasal photodisinfection technology, Steriwave, has been shortlisted as a finalist for the 2025 Bionow Product of the Year Award, a recognition that comes amid record nomination levels and highlights the product&#...
Business Operations and StrategyProduct-Related Announcements
Ondine’s Steriwave Chosen for Infection Control at New CAD$1.4bn Cowichan Hospital
Positive
Jan 27, 2026
Ondine Biomedical Inc. has secured another Canadian hospital deployment for its Steriwave nasal photodisinfection system, as Cowichan District Hospital within British Columbia’s Island Health Authority adopts the technology as a standard pre...
Business Operations and StrategyProduct-Related Announcements
Ondine’s Steriwave Enters Spanish ENT Surgery as Non‑Antibiotic Infection Control Tool
Positive
Jan 22, 2026
Ondine Biomedical has expanded the use of its Steriwave nasal photodisinfection technology into a leading ear, nose and throat surgical group with centres in Madrid and Málaga, targeting patients undergoing sinonasal procedures, including tho...
Business Operations and StrategyProduct-Related Announcements
Ondine Cites Landmark Microbiome Study to Back Universal Nasal Photodisinfection
Positive
Jan 13, 2026
Ondine Biomedical has highlighted new evidence from a landmark Nature Communications study of the nasal microbiome that supports the company’s photodisinfection technology as an alternative to traditional antibiotic-based nasal decolonisatio...
Business Operations and StrategyProduct-Related Announcements
Ondine Biomedical Gains Second National UK Award Shortlisting for Infection-Prevention Partnership
Positive
Dec 23, 2025
Ondine Biomedical and Mid Yorkshire Teaching NHS Trust have been shortlisted for the 2026 Excellence in Healthcare Partnership Awards for their collaboration using Ondine’s Steriwave nasal photodisinfection technology to reduce surgical site...
Business Operations and StrategyProduct-Related Announcements
Ondine Biomedical Launches First German Hospital Trial of Steriwave with LMU Munich
Positive
Dec 22, 2025
Ondine Biomedical has entered a research collaboration with LMU University Hospital Munich to pilot its Steriwave nasal photodisinfection technology in ear, nose and throat patients, marking the first deployment of the platform in a German hospita...
Business Operations and Strategy
Ondine Biomedical Shortlisted for Prestigious HSJ Partnership Award
Positive
Dec 16, 2025
Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have been shortlisted for the ‘Most Impactful Use of Technology on Clinical Practice’ award at the 2026 HSJ Partnership Awards. This recognition follows the successful impleme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.